Citoxlab, a CRO for nonclinical research, has tapped Christophe Berthoux as chief executive for its European operations.
Berthoux has spent more than a quarter-century in the CRO industry, most recently as chief executive of U.K.-based clinical SMO Synexus. Previously, Berthoux held a number of positions at Charles River Laboratories.
“Following the recent acquisition of Solvo, Citoxlab now has six research centers in Europe (France, Hungary and Denmark),” Dr. Jean-François Le Bigot, president and CEO of Citoxlab group, said in a statement. “In this context, it became clear that we needed to reinforce our management structure.”
Citoxlab picked up Hungary-based Solvo in March for an undisclosed price. With Solvo, which works in the expanding area of investigating the transport mechanisms pivotal in drug development, Citoxlab got 100 staffers and a new offering in the form of drug transporter studies and the assessment of Drug-Drug Interactions.
“At this time there are a lot of changes in pharma and biotech R&D,” Berthoux said in a statement. “As a scientifically driven CRO, I am convinced that Citoxlab has a lot of opportunities for future growth.”